Protein Flexibility in Virtual Screening: The BACE-1 Case Study
暂无分享,去创建一个
David S. Goodsell | Arthur J. Olson | Ettore Novellino | Francesca Mancini | Luciana Marinelli | Sandro Cosconati | Angela De Simone | Vincenza Andrisano | Francesco Saverio Di Leva | Valeria La Pietra | D. Goodsell | E. Novellino | V. Andrisano | A. Olson | F. Mancini | L. Marinelli | S. Cosconati | A. Simone | F. S. D. Leva | V. Pietra
[1] M Katharine Holloway,et al. Identification of a small molecule nonpeptide active site beta-secretase inhibitor that displays a nontraditional binding mode for aspartyl proteases. , 2004, Journal of medicinal chemistry.
[2] David S Goodsell,et al. Structure-based virtual screening and biological evaluation of Mycobacterium tuberculosis adenosine 5'-phosphosulfate reductase inhibitors. , 2008, Journal of medicinal chemistry.
[3] Lin Hong,et al. Structural locations and functional roles of new subsites S5, S6, and S7 in memapsin 2 (beta-secretase). , 2005, Biochemistry.
[4] Migliore Amico. Ensemble-docking approach on BACE-1 : Pharmacophore Perception and Guidelines for Drug Design , .
[5] B. Shoichet,et al. Soft docking and multiple receptor conformations in virtual screening. , 2004, Journal of medicinal chemistry.
[6] A. Leach,et al. Ligand docking to proteins with discrete side-chain flexibility. , 1994, Journal of molecular biology.
[7] Natasja Brooijmans,et al. Molecular recognition and docking algorithms. , 2003, Annual review of biophysics and biomolecular structure.
[8] Sahil Patel,et al. Apo and Inhibitor Complex Structures of BACE (β-secretase) , 2004 .
[9] Alison R. Gregro,et al. Structure-based design of potent and selective cell-permeable inhibitors of human beta-secretase (BACE-1). , 2004, Journal of medicinal chemistry.
[10] A. di Nola,et al. Docking of flexible ligands to flexible receptors in solution by molecular dynamics simulation , 1999, Proteins.
[11] Stefano Forli,et al. Virtual screening with AutoDock: theory and practice , 2010, Expert opinion on drug discovery.
[12] Ettore Novellino,et al. Pursuing aldose reductase inhibitors through in situ cross-docking and similarity-based virtual screening. , 2009, Journal of medicinal chemistry.
[13] I Lasters,et al. Computation of the binding of fully flexible peptides to proteins with flexible side chains , 1997, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[14] Thomas Lengauer,et al. FlexE: efficient molecular docking considering protein structure variations. , 2001, Journal of molecular biology.
[15] D. Goodsell,et al. Automated docking to multiple target structures: Incorporation of protein mobility and structural water heterogeneity in AutoDock , 2002, Proteins.
[16] C. Chung,et al. Effect of detergent on "promiscuous" inhibitors. , 2003, Journal of medicinal chemistry.
[17] Ernst Althaus,et al. A combinatorial approach to protein docking with flexible side-chains , 2000, RECOMB '00.
[18] David S. Goodsell,et al. A semiempirical free energy force field with charge‐based desolvation , 2007, J. Comput. Chem..
[19] Ettore Novellino,et al. Tandem application of virtual screening and NMR experiments in the discovery of brand new DNA quadruplex groove binders. , 2009, Journal of the American Chemical Society.
[20] M L Teodoro,et al. Conformational flexibility models for the receptor in structure based drug design. , 2003, Current pharmaceutical design.
[21] Arun K. Ghosh,et al. Developing β‐secretase inhibitors for treatment of Alzheimer’s disease , 2012, Journal of neurochemistry.
[22] Boris Schmidt,et al. Ensemble‐Docking Approach on BACE‐1: Pharmacophore Perception and Guidelines for Drug Design , 2007 .
[23] Christopher W Murray,et al. Apo and inhibitor complex structures of BACE (beta-secretase). , 2004, Journal of molecular biology.
[24] Michel F. Sanner,et al. Protein–ligand docking with multiple flexible side chains , 2008, J. Comput. Aided Mol. Des..
[25] Lin Hong,et al. Structure-based design of cycloamide–urethane-derived novel inhibitors of human brain memapsin 2 (β-secretase) , 2005 .
[26] Vincenza Andrisano,et al. Beta-secretase as a target for Alzheimer’s disease drug discovery: an overview of in vitro methods for characterization of inhibitors , 2011, Analytical and bioanalytical chemistry.
[27] S. Teague. Implications of protein flexibility for drug discovery , 2003, Nature Reviews Drug Discovery.
[28] Heather A Carlson,et al. Protein flexibility is an important component of structure-based drug discovery. , 2002, Current pharmaceutical design.
[29] J A McCammon,et al. Accommodating protein flexibility in computational drug design. , 2000, Molecular pharmacology.
[30] Andreas Plückthun,et al. Docking small ligands in flexible binding sites , 1998 .
[31] Dennis M. Krüger,et al. Comparison of Structure‐ and Ligand‐Based Virtual Screening Protocols Considering Hit List Complementarity and Enrichment Factors , 2010, ChemMedChem.
[32] Hanna Geppert,et al. Integrating Structure‐ and Ligand‐Based Virtual Screening: Comparison of Individual, Parallel, and Fused Molecular Docking and Similarity Search Calculations on Multiple Targets , 2008, ChemMedChem.
[33] Lin Hong,et al. Structure-based design of cycloamide-urethane-derived novel inhibitors of human brain memapsin 2 (beta-secretase). , 2005, Bioorganic & medicinal chemistry letters.
[34] Lin Hong,et al. Design, synthesis and X-ray structure of protein-ligand complexes: important insight into selectivity of memapsin 2 (beta-secretase) inhibitors. , 2006, Journal of the American Chemical Society.
[35] Lin Hong,et al. Design, Synthesis and X-ray Structure of Protein−Ligand Complexes: Important Insight into Selectivity of Memapsin 2 (β-Secretase) Inhibitors , 2006 .
[36] Ettore Novellino,et al. Human recombinant beta-secretase immobilized enzyme reactor for fast hits' selection and characterization from a virtual screening library. , 2013, Journal of pharmaceutical and biomedical analysis.
[37] Junya Qu,et al. 2-Amino-3,4-dihydroquinazolines as inhibitors of BACE-1 (beta-site APP cleaving enzyme): Use of structure based design to convert a micromolar hit into a nanomolar lead. , 2007, Journal of medicinal chemistry.
[38] Michael S. Wolfe. Secretase Targets for Alzheimer′s Disease: Identification and Therapeutic Potential , 2001 .
[39] Robert A Copeland,et al. An inhibitor binding pocket distinct from the catalytic active site on human beta-APP cleaving enzyme. , 2005, Biochemistry.
[40] S. Kim,et al. "Soft docking": matching of molecular surface cubes. , 1991, Journal of molecular biology.
[41] L Hong,et al. Structure of the protease domain of memapsin 2 (beta-secretase) complexed with inhibitor. , 2000, Science.
[42] Brian K Shoichet,et al. Testing a flexible-receptor docking algorithm in a model binding site. , 2004, Journal of molecular biology.
[43] Rikard Emanuelsson,et al. Investigation of α-phenylnorstatine and α-benzylnorstatine as transition state isostere motifs in the search for new BACE-1 inhibitors. , 2011, Bioorganic & medicinal chemistry.
[44] J. Irwin,et al. ZINC ? A Free Database of Commercially Available Compounds for Virtual Screening. , 2005 .
[45] J. Mccammon,et al. Molecular recognition in the case of flexible targets. , 2011, Current pharmaceutical design.
[46] Ernst Althaus,et al. A Combinatorial Approach to Protein Docking with Flexible Side Chains , 2002, J. Comput. Biol..